Press coverage about AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. AEterna Zentaris earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.3031995344878 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:

AEZS has been the topic of a number of analyst reports. Maxim Group increased their price objective on AEterna Zentaris from $2.00 to $4.00 and gave the company a “buy” rating in a report on Wednesday, July 19th. Zacks Investment Research raised AEterna Zentaris from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. ValuEngine raised AEterna Zentaris from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, HC Wainwright set a $3.00 target price on AEterna Zentaris and gave the company a “buy” rating in a report on Wednesday, July 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. AEterna Zentaris presently has an average rating of “Hold” and a consensus price target of $4.33.

Shares of AEterna Zentaris (NASDAQ AEZS) opened at 2.12 on Friday. AEterna Zentaris has a 12-month low of $0.78 and a 12-month high of $5.59. The firm’s market cap is $34.15 million. The firm has a 50-day moving average price of $1.99 and a 200-day moving average price of $1.80.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.05). The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.22 million. AEterna Zentaris had a negative return on equity of 514.64% and a negative net margin of 1,945.78%. AEterna Zentaris’s revenue was up 153.1% compared to the same quarter last year. Equities research analysts anticipate that AEterna Zentaris will post ($1.02) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect AEterna Zentaris (AEZS) Stock Price” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at

About AEterna Zentaris

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Insider Buying and Selling by Quarter for AEterna Zentaris (NASDAQ:AEZS)

Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with's FREE daily email newsletter.